Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by 48thHighlanderon Jun 24, 2018 4:22pm
111 Views
Post# 28221097

RE:The elusive butterfly of love

RE:The elusive butterfly of love
DrHoliday wrote: "Oh, Hoto is going dancing to LaLaland to pick daisies and buttercups and chase elusive PDP butterflies now that he is out of ICO, and then to sow doubt here while pumping up his new play".

It would appear that he himself has forgotten the bullish investment case for ICO, or is he a scalper in reality merely trying to bash ICO lower for a repurchase? If you follow the money, you will realize that the big players did indeed take a profit, but understand the size of the market and how Oral B Amphotericin could be a game changer and challenge Gilead's  billion dollar market share for the injectable version which has been around for 50 years. If you think that AstraZeneca has no interest in Oral B, then you are sadly mistaken. I don't know when the US32 million dollar milestone payment option must be paid. It might not be until successful Phase 3 trials. Meanwhile, ICO could easily do a small financing at a premium to the market and close it in a done deal in a heartbeat just to tide them over to continue work and proceed to Phase 2.

Mark my words that AstraZeneca will be watching ICO for phase 1 trial results in July, and taking
an eqity stake in ICO would be a strategic move, and help to defend against any hostility by unfriendly competitors who do not want to lose market share to Oral B Amphotericin.

https://www.youtube.com/watch?v=2JyMGb-d8Io


THIS !!! is what I mean by informed postimg....well done good doctor..well done !!

Place this with a few other very great information/discussion based posts this weekend and a picture emerges....

YES... the CEO would "intimately"  know whats going on.in his own fiefdom....
NO.... Astra-Zeneca would not let a multi billion dollar asset go for want of 32 million....
<< Previous
Bullboard Posts
Next >>